Conceivably RB B-ADVP, , Oin IN B-PPa DT B-NPscaled-back JJ I-NPbuy-out NN I-NP, , Othey PRP B-NPcould MD B-VPbe VB I-VPbumped VBN I-VPback RB B-ADVPto TO B-PPcoach NN B-NPseats NNS I-NPfor IN B-PPlife NN B-NP. . OThomas NNP B-NPH. NNP I-NPJohnson NNP I-NP, , Opresident NN B-NPof IN B-PPthe DT B-NPCoatedboard NNP I-NPdivision NN I-NPof IN B-PPMead NNP B-NPCorp. NNP I-NP, , Owas VBD B-VPnamed VBN I-VPpresident NN B-NPof IN B-PPManville NNP B-NPForest NNP I-NPProducts NNP I-NPCorp. NNP I-NP, , Oa DT B-NPManville NNP I-NPunit NN I-NP, , Oand CC Osenior JJ B-NPvice NN I-NPpresident NN I-NPof IN B-PPManville NNP B-NPCorp NNP I-NP. . OMr. NNP B-NPJohnson NNP I-NPsucceeds VBZ B-VPHarry NNP B-NPW. NNP I-NPSherman NNP I-NP, , Owho WP B-NPresigned VBD B-VPto TO B-VPpursue VB I-VPother JJ B-NPinterests NNS I-NP, , Oin IN B-PPboth DT B-NPpositions NNS I-NP. . OManville NNP B-NPis VBZ B-VPa DT B-NPbuilding NN I-NPand CC I-NPforest NN I-NPproducts NNS I-NPconcern VBP I-NP. . OUS PRP B-NPFacilities NNP I-NPCorp. NNP I-NPsaid VBD B-VPRobert NNP B-NPJ. NNP I-NPPercival NNP I-NPagreed VBD B-VPto TO I-VPstep VB I-VPdown RB B-ADVPas IN B-PPvice NN B-NPchairman NN I-NPof IN B-PPthe DT B-NPinsurance NN I-NPholding VBG I-NPcompany NN I-NP. . O`` `` OThere EX B-NPwas VBD B-VPa DT B-NPdifference NN I-NPof IN B-PPopinion NN B-NPas IN B-PPto TO B-PPthe DT B-NPfuture NN I-NPdirection NN I-NPof IN B-PPthe DT B-NPcompany NN I-NP, , O'' '' Oa DT B-NPspokeswoman NN I-NPsaid VBD B-VP. . OMr. NNP B-NPPercival NNP I-NPdeclined VBD B-VPto TO I-VPcomment VB I-VP. . OIn IN B-PPa DT B-NPstatement NN I-NP, , OUS PRP B-NPFacilities NNPS I-NPsaid VBD B-VPMr. NNP B-NPPercival NNP I-NP's POS B-NPemployment NN I-NPcontract NN I-NPcalls VBZ B-VPfor IN B-SBARhim PRP B-NPto TO B-VPact VB I-VPas IN B-PPa DT B-NPconsultant NN I-NPto TO B-PPthe DT B-NPcompany NN I-NPfor IN B-PPtwo CD B-NPyears NNS I-NP. . OHe PRP B-NPwill MD B-VPalso RB I-VPremain VB I-VPa DT B-NPdirector NN I-NP, , OUS PRP B-NPFacilities NNPS I-NPsaid VBD B-VP, , Obut CC Owo MD B-VPn't RB I-VPserve VB I-VPon IN B-PPany DT B-NPboard NN I-NPcommittees NNS I-NP. . OMr. NNP B-NPPercival NNP I-NPwill MD B-VPbe VB I-VPsucceeded VBN I-VPon IN B-PPan DT B-NPinterim JJ I-NPbasis NN I-NPby IN B-PPGeorge NNP B-NPKadonada NNP I-NP, , OUS PRP B-NPFacilities NNPS I-NPchairman NN I-NPand CC I-NPpresident NN I-NP. . OIn IN B-PPthe DT B-NPsame JJ I-NPstatement NN I-NP, , OUS PRP B-NPFacilities NNPS I-NPalso RB B-ADVPsaid VBD B-VPit PRP B-NPhad VBD B-VPbought VBN I-VPback RB B-ADVP112,000 CD B-NPof IN B-PPits PRP$ B-NPcommon JJ I-NPshares NNS I-NPin IN B-PPa DT B-NPprivate JJ I-NPtransaction NN I-NP. . OTerms NNS B-NPwere VBD B-VPn't RB I-VPdisclosed VBN I-VP. . OThe DT B-NPbuy-back NN I-NPrepresents VBZ B-VPabout IN B-NP3 CD I-NP% NN I-NPof IN B-PPthe DT B-NPcompany NN I-NP's POS B-NPshares NNS I-NP, , Obased VBN B-VPon IN B-PPthe DT B-NP3.7 CD I-NPmillion CD I-NPshares NNS I-NPoutstanding JJ B-ADJPas IN B-PPof IN B-PPSept. NNP B-NP30 CD I-NP. . OIn IN B-PPnational JJ B-NPover-the-counter JJ I-NPtrading NN I-NPyesterday NN B-NP, , OUS PRP B-NPFacilities NNPS I-NPclosed VBD B-VPat IN B-PP$ $ B-NP3.625 CD I-NP, , Ounchanged JJ B-ADJP. . OThree CD B-NPleading VBG I-NPdrug NN I-NPcompanies NNS I-NPreported VBD B-VProbust JJ B-NPthird-quarter JJ I-NPearnings NNS I-NP, , Obolstered VBN B-VPby IN B-PPstrong JJ B-NPsales NNS I-NPof IN B-PPnewer JJR B-NP, , I-NPbig-selling JJ I-NPprescriptions NNS I-NPdrugs NNS I-NPthat WDT B-NPprovide VBP B-VPhefty JJ B-NPprofit NN I-NPmargins NNS I-NP. . OMerck NNP B-NP& CC I-NPCo. NNP I-NPreported VBD B-VPa DT B-NP25 CD I-NP% NN I-NPincrease NN I-NPin IN B-PPearnings NNS B-NP; : OWarner-Lambert NNP B-NPCo. NNP I-NP's POS B-NPprofit NN I-NProse VBD B-VP22 CD B-NP% NN I-NPand CC OEli NNP B-NPLilly NNP I-NP& CC I-NPCo. NNP I-NP's POS B-NPnet JJ I-NPincome NN I-NProse VBD B-VP24 CD B-NP% NN I-NP. . OThe DT B-NPresults NNS I-NPwere VBD B-VPin IN B-PPline NN B-NPwith IN B-PPanalysts NNS B-NP' POS B-NPexpectations NNS I-NP. . OMerck NNP B-NP& CC I-NPCo NNP I-NP. . OMerck NNP B-NP, , ORahway NNP B-NP, , ON.J. NNP B-NP, , Ocontinued VBD B-VPto TO I-VPlead VB I-VPthe DT B-NPindustry NN I-NPwith IN B-PPa DT B-NPstrong JJ I-NPsales NNS I-NPperformance NN I-NPin IN B-PPthe DT B-NPhuman NN I-NPand CC I-NPanimal NN I-NPhealth-products NNS I-NPsegment VBP I-NP. . OA DT B-NPstronger JJR I-NPU.S. NNP I-NPdollar NN I-NPreduced VBD B-VPthird-quarter JJ B-NPand CC I-NPfirst-nine-month JJ I-NPsales NNS I-NPgrowth NN I-NP2 CD B-NP% NN I-NPand CC I-NP3 CD I-NP% NN I-NP, , Orespectively RB B-ADVP. . OInternational JJ B-NPsales NNS I-NPaccounted VBD B-VPfor IN B-PP47 CD B-NP% NN I-NPof IN B-PPtotal JJ B-NPcompany NN I-NPsales NNS I-NPfor IN B-PPthe DT B-NPnine CD I-NPmonths NNS I-NP, , Ocompared VBN B-PPwith IN B-PP50 CD B-NP% NN I-NPa DT B-NPyear NN I-NPearlier RBR B-ADVP. . OSales NNS B-NPfor IN B-PPthe DT B-NPquarter NN I-NProse VBD B-VPto TO B-PP$ $ B-NP1.63 CD I-NPbillion CD I-NPfrom IN B-PP$ $ B-NP1.47 CD I-NPbillion CD I-NP. . OMevacor NNP B-NP, , OMerck NNP B-NP's POS B-NPnew JJ I-NPcholesterol-lowering JJ I-NPdrug NN I-NP, , Ohad VBD B-VPhigher JJR B-NPsales NNS I-NPthan IN B-SBARany DT B-NPother JJ I-NPprescription NN I-NPmedicine NN I-NPhas VBZ B-VPever RB I-VPachieved VBN I-VPin IN B-PPthe DT B-NPU.S. NNP I-NPin IN B-PPthe DT B-NPyear NN I-NPfollowing VBG B-PPintroduction NN B-NP, , Othe DT B-NPcompany NN I-NPsaid VBD B-VP. . OThe DT B-NPdrug NN I-NPwas VBD B-VPintroduced VBN I-VPin IN B-PPWest NNP B-NPGermany NNP I-NPthis DT B-NPyear NN I-NP. . OIntense JJ B-NPcompetition NN I-NP, , Ohowever RB B-ADVP, , Oled VBN B-VPto TO B-PPunit NN B-NPsales NNS I-NPdeclines NNS I-NPfor IN B-PPa DT B-NPgroup NN I-NPof IN B-PPMerck NNP B-NP's POS B-NPestablished VBN I-NPhuman NN I-NPand CC I-NPanimal-health NN I-NPproducts NNS I-NP, , Oincluding VBG B-PPAldomet NNP B-NPand CC I-NPIndocin NNP I-NP. . OIn IN B-PPNew NNP B-NPYork NNP I-NPStock NNP I-NPExchange NNP I-NPcomposite JJ I-NPtrading NN I-NPyesterday NN B-NP, , OMerck NNP B-NPshares NNS I-NPclosed VBD B-VPat IN B-PP$ $ B-NP75.25 CD I-NP, , Oup IN B-ADVP50 CD B-NPcents NNS I-NP. . OWarner-Lambert NNP B-NPCo NNP I-NP. . OWarner-Lambert NNP B-NP, , OMorris NNP B-NPPlains NNP I-NP, , ON.J. NNP B-NP, , Oreported VBD B-VPsales NNS B-NPthat WDT B-NPwere VBD B-VPa DT B-NPrecord NN I-NPfor IN B-PPany DT B-NPquarter NN I-NPand CC Othe DT B-NPeighth JJ I-NPquarter NN I-NPin IN B-PPa DT B-NProw NN I-NPof IN B-PP20 CD B-NP% NN I-NPor CC I-NPmore RBR I-NPper-share JJ I-NPearnings NNS I-NPgrowth NN I-NP. . OSpurred VBN B-VPby IN B-PPgrowth NN B-NPin IN B-PPworld-wide JJ B-NPsales NNS I-NPof IN B-PPthe DT B-NPcompany NN I-NP's POS B-NPprescription NN I-NPdrugs NNS I-NP, , OWarner-Lambert NNP B-NPsaid VBD B-VP1989 CD B-NPwill MD B-VPbe VB I-VPthe DT B-NPbest JJS I-NPyear NN I-NPin IN B-PPits PRP$ B-NPhistory NN I-NP, , Owith IN B-SBARper-share JJ B-NPearnings NNS I-NPexpected VBN B-VPto TO I-VPincrease VB I-VPmore JJR B-NPthan IN I-NP20 CD I-NP% NN I-NPto TO B-PPabout RB B-NP$ $ I-NP6.10 CD I-NP. . OSales NNS B-NPfor IN B-PPthe DT B-NPquarter NN I-NProse VBD B-VPto TO B-PP$ $ B-NP1.11 CD I-NPbillion CD I-NPfrom IN B-PP$ $ B-NP1.03 CD I-NPbillion CD I-NP. . OPrescription-drug NN B-NPworld-wide JJ I-NPsales NNS I-NProse VBD B-VP9 CD B-NP% NN I-NPin IN B-PPthe DT B-NPquarter NN I-NPto TO B-PP$ $ B-NP340 CD I-NPmillion CD I-NP; : OU.S. NNP B-NPsales NNS I-NProse VBD B-VP15 CD B-NP% NN I-NP. . OThe DT B-NPsegment NN I-NP's POS B-NPgrowth NN I-NPwas VBD B-VPled VBN I-VPby IN B-PPsales NNS B-NPof IN B-PPthe DT B-NPcardiovascular JJ I-NPdrugs NNS I-NPLopid NNP B-NP, , Oa DT B-NPlipid NN I-NPregulator NN I-NP, , Oand CC ODilzem NNP B-NP, , Oa DT B-NPcalcium NN I-NPchannel NN I-NPblocker NN I-NP. . OWorld-wide JJ B-NPsales NNS I-NPof IN B-PPWarner-Lambert NNP B-NP's POS B-NPnon-prescription JJ I-NPhealth-care NN I-NPproducts NNS I-NP, , Osuch JJ B-PPas IN I-PPHalls NNP B-NPcough NN I-NPtablets NNS I-NP, , ORolaids NNP B-NPantacid NN I-NP, , Oand CC OLubriderm NNP B-NPskin NN I-NPlotion NN I-NP, , Oincreased VBN B-VP3 CD B-NP% NN I-NPto TO B-PP$ $ B-NP362 CD I-NPmillion CD I-NPin IN B-PPthe DT B-NPthird JJ I-NPquarter NN I-NP; : OU.S. NNP B-NPsales NNS I-NProse VBD B-VP5 NN B-NP% NN I-NP. . OConfectionery JJ B-NPproducts NNS I-NPsales NNS I-NPalso RB B-ADVPhad VBD B-VPstrong JJ B-NPgrowth NN I-NPin IN B-PPthe DT B-NPquarter NN I-NP. . OWorld-wide JJ B-NPsales NNS I-NPof IN B-PPTrident NNP B-NPgum NN I-NP, , OCerts NNP B-NPbreath NN I-NPmints NNS I-NP, , Oand CC OClorets NNP B-NPgum NN I-NPand CC I-NPbreath NN I-NPmints NNS I-NP, , Oincreased VBN B-VP12 CD B-NP% NN I-NPto TO B-PP$ $ B-NP277 CD I-NPmillion CD I-NP. . OWarner-Lambert NNP B-NPshares NNS I-NPclosed VBD B-VPat IN B-PP$ $ B-NP109.50 CD I-NPa DT B-NPshare NN I-NP, , Oup IN B-ADVP$ $ B-NP1.50 CD I-NP, , Oin IN B-PPBig NNP B-NPBoard NNP I-NPcomposite JJ I-NPtrading NN I-NPyesterday NN B-NP. . OEli NNP B-NPLilly NNP I-NP& CC I-NPCo NNP I-NP. . OLilly NNP B-NPattributed VBD B-VPrecord NN B-NPthird-quarter JJ I-NPand CC I-NPnine-month JJ I-NPresults NNS I-NPto TO B-PPworld-wide JJ B-NPgains NNS I-NPfor IN B-PPpharmaceuticals NNS B-NP, , Omedical JJ B-NPinstruments NNS I-NPand CC Oplant-science NN B-NPproducts NNS I-NPdespite IN B-PPpoor JJ B-NPexchange NN I-NPrates NNS I-NPfor IN B-PPthe DT B-NPdollar NN I-NPthat WDT B-NPslowed VBD B-VPsales NNS B-NPabroad RB B-ADVP. . OEarnings NNS B-NPcontinued VBD B-VPto TO I-VPpace VB I-VPsales NNS B-NPbecause IN B-PPof IN I-PPa DT B-NPlower JJR I-NPtax NN I-NPrate NN I-NP, , Oprofit NN B-NPfrom IN B-PPthe DT B-NPrenegotiation NN I-NPof IN B-PPthe DT B-NPdebt NN I-NPinstrument NN I-NPreceived VBD B-VPfrom IN B-PPFaberge NNP B-NPInc. NNP I-NPin IN B-PPconnection NN B-NPwith IN B-PPLilly NNP B-NP's POS B-NPsale NN I-NPof IN B-PPElizabeth NNP B-NPArden NNP I-NPInc. NNP I-NPin IN B-PP1987 CD B-NP, , Oand CC Onet JJ B-NPproceeds NNS I-NPfrom IN B-PPthe DT B-NPsettlement NN I-NPof IN B-PPpatent NN B-NPlitigation NN I-NPat IN B-PPLilly NNP B-NP's POS B-NPHybritech NNP I-NPInc. NNP I-NPunit NN I-NP. . OThird-quarter JJ B-NPsales NNS I-NPof IN B-PPthe DT B-NPIndianapolis NNP I-NP, , I-NPInd. NNP I-NP, , I-NPcompany NN I-NProse VBD B-VP11 CD B-NP% NN I-NPto TO B-PP$ $ B-NP1.045 CD I-NPbillion CD I-NPfrom IN B-PP$ $ B-NP940.6 CD I-NPmillion CD I-NP. . ONine-month JJ B-NPsales NNS I-NPgrew VBD B-VP12 CD B-NP% NN I-NPto TO B-PP$ $ B-NP3.39 CD I-NPbillion CD I-NPfrom IN B-PP$ $ B-NP3.03 CD I-NPbillion CD I-NPa DT B-NPyear NN I-NPearlier RBR B-ADVP. . OSales NNS B-NPof IN B-PPProzac NNP B-NP, , Oan DT B-NPanti-depressant NN I-NP, , Oled VBN B-VPdrug-sales NNS B-NPincreases NNS I-NP. . OHigher JJR B-NPsales NNS I-NPof IN B-PPpesticides NNS B-NPand CC Oother JJ B-NPplant-science NN I-NPproducts NNS I-NPmore JJR B-VPthan IN I-VPoffset VB I-VPa DT B-NPslight JJ I-NPdecline NN I-NPin IN B-PPthe DT B-NPsales NNS I-NPof IN B-PPanimal-health NN B-NPproducts NNS I-NPto TO B-VPfuel VB I-VPthe DT B-NPincrease NN I-NPin IN B-PPworld-wide JJ B-NPagricultural JJ I-NPproduct NN I-NPsales NNS I-NP, , OLilly NNP B-NPsaid VBD B-VP. . OAdvanced NNP B-NPCardiovascular NNP I-NPSystems NNP I-NPInc. NNP I-NPand CC OCardiac NNP B-NPPacemakers NNPS I-NPInc. NNP I-NPunits NNS I-NPled VBD B-VPgrowth NN B-NPin IN B-PPthe DT B-NPmedical-instrument JJ I-NPsystems NNS I-NPdivision NN I-NP. . OLilly NNP B-NPshares NNS I-NPclosed VBD B-VPyesterday NN B-NPin IN B-PPcomposite JJ B-NPtrading NN I-NPon IN B-PPthe DT B-NPBig NNP I-NPBoard NNP I-NPat IN B-PP$ $ B-NP62.25 CD I-NP, , Odown RB B-ADVP12.5 CD B-NPcents NNS I-NP. . OReuben NNP B-NPMark NNP I-NP, , Ochairman NN B-NPof IN B-PPColgate-Palmolive NNP B-NPCo. NNP I-NP, , Osaid VBD B-VPhe PRP B-NPis VBZ B-VP`` `` B-ADJPcomfortable JJ I-ADJP'' '' Owith IN B-PPanalysts NNS B-NP' POS B-NPestimates NNS I-NPthat IN B-SBARthird-quarter JJ B-NPearnings NNS I-NProse VBD B-VPto TO B-PPbetween IN B-NP95 CD I-NPcents NNS I-NPand CC I-NP$ $ I-NP1.05 CD I-NPa DT B-NPshare NN I-NP. . OThat DT B-NPcompares VBZ B-VPwith IN B-PPper-share JJ B-NPearnings NNS I-NPfrom IN B-PPcontinuing VBG B-NP